Pharma’s “patent cliff” isn’t just about expiring patents. It’s about how those patents are written.
For years, the industry has treated the patent cliff like a calendar problem: a handful of years, a wave of generics, a predictable hit to revenue. But…

The Patent Dance Is No Longer a Game of Guessing—It’s a Game of Timing.
If you’ve been anywhere near biosimilars, you’ve heard the phrase: the patent dance. It sounds procedural—almost bureaucratic. But in practice, it’s where fortunes are made (or qui…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

Blockbuster patents aren’t just legal documents—they’re engineering blueprints.
If you’ve ever wondered how competitors “magically” arrive at a viable design-around for a blockbuster drug, the answer is rarely magic. It’s usually forensics: a discipl…

Patent risk isn’t just a legal problem—it’s a board-level governance problem.
For years, pharma leaders treated IP litigation like a downstream event: something handled by counsel, managed by outside firms, and resolved on a timeline that rarely matche…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

Pharma forensics is the new competitive intelligence.
Most people think formulation patents are “just chemistry.” In reality, they’re often the most strategic documents in a company’s lifecycle playbook—quietly encoding timelines, manufacturing const…

Designing Around the Moat: How Generic Developers Can Win the Secondary-Patent Game
In generic drug development, the first patent is rarely the whole story.
Most teams plan their strategy around the “primary” patent landscape—mechanism-of-action, compo…

Patent cliffs aren’t just a legal event—they’re a supply-chain stress test.
If you work in pharma operations, procurement, or commercial planning, you’ve probably felt the same pattern: a blockbuster’s exclusivity window closes, competitors surge, pric…